InflaRx (IFRX) EBIT (QoQ) (2017 - 2026)
InflaRx (IFRX) EBIT (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | InflaRx | 138.61 Mn | -45.64 Mn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.48% |
| Dec 31, 2025 | 471.94% |
| Sep 30, 2025 | 24.23% |
| Jun 30, 2025 | -6.89% |
| Mar 31, 2025 | -129.60% |
| Dec 31, 2024 | 373.95% |
| Sep 30, 2024 | -1.74% |
| Jun 30, 2024 | -22.21% |
| Mar 31, 2024 | 5.23% |
| Dec 31, 2023 | -17.94% |
| Sep 30, 2023 | -13.10% |
| Jun 30, 2023 | -94,378,474.06% |
| Mar 31, 2023 | 100.00% |
| Dec 31, 2022 | 9.36% |
| Sep 30, 2022 | -647.32% |
| Jun 30, 2022 | 93.05% |
| Mar 31, 2022 | -12.17% |
| Dec 31, 2021 | 0.99% |
| Sep 30, 2021 | 10.83% |
| Jun 30, 2021 | -76.16% |